Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003 : Original article  

PARP as disease target: endotoxic shock

P. Radermacher

Med Sci Monit 2003; 9(1): 58- :: ID: 15197


The activation of PARP is attributed a crucial role in the development of multiple organ failure induced by endotoxemia, sepsis and septic shock, in particular as a result of compromised vascular contractility [1] and endothelial vasorelaxation [2], impaired mitochondrial respiration [3], and pulmonary as well as intestinal hyperpermeability [4]. Therefore, the therapeutic potential of PARP-inhibition has been investigated in endotoxic shock using nicotinamide, 3-aminobenzamide and phenantridinones. Nicotinamide, which was originally tested as a substrate supplement already 30 years ago [5], not only to is a (weak) PARP-inhibitor but also reduced NO [6, 7] and cytokine formation [8]. Results are controversial in vivo: while it stabilized hemodynamics, attenuated acute lung injury and ultimately improved survival in some studies [9,10], it failed to prevent lactic acidosis and renal or hepatic injury in others [11]. In our long term model of hyperdynamic porcine endotoxemia which is characterized by a sustained increase in cardiac output and thus mimicks the clinical scenario of human septic shock, nicotinamide did not have any beneficial effect on the endotoxin-induced metabolic disturbances [12]. 3-aminobenzamide, the ‘classical’ PARP-inhibitor used in endotoxic shock models, not only attenuated the LPS-induced vascular failure in vitro, but also reduced the pulmonary and intestinal microvascular injury and thus improved the mucosal barrier function [4, 13]. Nevertheless, in other models 3-aminobenzamide also failed to prevent visceral organ dysfunction [11], and in short term porcine endotoxemia it did not influence the LPS-induced effects on the systemic and pulmonary hemodynamics [14]. Most recently, the novel and highly PARP-1-selective phenanthridinones [15] were reported to prevent vascular failure and acute lung injury in rat endotoxic shock [16]. Moreover, used as a pretreatment, they preserved myocardial contractility both in endotoxin-injected rats [17] and porcine polymicrobial peritonitis [18]. Finally, in our endotoxmic swine model they improved stroke volume and blunted the otherwise progressive intestinal mucosal acidosis [19]. Taken together, nicotinamide showed controversial efficacy in the treatment of endotoxic shock, probably due to its relatively poor activity as a PARP-inhibitor and due to the potential hepatotoxicity when administered in high doses. By contrast, the currently available data study support the hypothesis that potent and selective PARP inhibitors may be of beneficial and therapeutic value in septic shock.

Keywords: endotoxin, Sepsis, nicotinamide, 3-aminobenzamide, phenanthridinone PARS inhibitors, rodent, Swine



01 May 2022 : Editorial  

Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.937048

Med Sci Monit 2022; 28:e937048


24 May 2022 : Clinical Research  

Screening for SARS-CoV-2 Infection in Students at the Medical University of Warsaw, Poland Between November...

Med Sci Monit In Press; DOI: 10.12659/MSM.936962  

04 May 2022 : Clinical Research  

Effects of Wearing Face Masks on Exercise Capacity and Ventilatory Anaerobic Threshold in Healthy Subjects ...

Med Sci Monit In Press; DOI: 10.12659/MSM.936069  

27 May 2022 : Clinical Research  

Factors Associated with Falls During Hospitalization for Coronavirus Disease 2019 (COVID-19)

Med Sci Monit 2022; 28:e936547

In Press

25 May 2022 : Review article  

Narrative Review of the Mechanism of Hip Prosthesis Dislocation and Methods to Reduce the Risk of Dislocation

Med Sci Monit In Press; DOI: 10.12659/MSM.935665  

24 May 2022 : Clinical Research  

Remimazolam Tosilate Sedation with Adjuvant Sufentanil in Chinese Patients with Liver Cirrhosis Undergoing ...

Med Sci Monit In Press; DOI: 10.12659/MSM.936580  

24 May 2022 : Clinical Research  

Screening for SARS-CoV-2 Infection in Students at the Medical University of Warsaw, Poland Between November...

Med Sci Monit In Press; DOI: 10.12659/MSM.936962  

23 May 2022 : Clinical Research  

Fully Automatic Knee Joint Segmentation and Quantitative Analysis for Osteoarthritis from Magnetic Resonanc...

Med Sci Monit In Press; DOI: 10.12659/MSM.936733  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750